Lisdexamfetamine: A pharmacokinetic review.

[1]  C. Bulik,et al.  Updates on Genome-wide Association Findings in Eating Disorders and Future Application to Precision Medicine , 2018, Current neuropharmacology.

[2]  M. Liechti,et al.  Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects , 2017, Front. Pharmacol..

[3]  J. Najib,et al.  Pharmacologic and Pharmacokinetic Aspects Lisdexamfetamine dimesylate is a water-soluble prodrug of the single isomer—d-amphetamine and l-lysine—that remains Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder , 2017 .

[4]  K. Lasseter,et al.  A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function , 2016, Therapeutic drug monitoring.

[5]  M. Corcoran,et al.  Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study , 2015, Drugs in R&D.

[6]  S. McElroy,et al.  Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. , 2015, JAMA psychiatry.

[7]  M. Corcoran,et al.  Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses , 2014, Journal of clinical psychopharmacology.

[8]  R. Secker,et al.  Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: A novel d-amphetamine pro-drug , 2014, Neuropharmacology.

[9]  M. Pennick,et al.  Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells , 2014, Neuropsychiatric disease and treatment.

[10]  D. Coghill,et al.  P.7.f.009 Lisdexamfetamine dimesylate: hydrolysis, pharmacokinetics and duration of therapeutic action in children and adolescents with ADHD , 2014, European Neuropsychopharmacology.

[11]  D. Coghill,et al.  A Systematic Review of the Safety of Lisdexamfetamine Dimesylate , 2014, CNS Drugs.

[12]  P. Mattos.  Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents , 2014 .

[13]  Tristan Shuman,et al.  Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation , 2014, Pharmacological Reviews.

[14]  Janet B W Williams.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[15]  M. Corcoran,et al.  Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate , 2013, Drugs in R&D.

[16]  K. Lasseter,et al.  An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults , 2013, Clinical Drug Investigation.

[17]  M. Pennick.  Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors* , 2013, Journal of drug assessment.

[18]  K. Lasseter,et al.  Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults , 2013, Neuropsychiatric disease and treatment.

[19]  Mats Johnson,et al.  Lisdexamfetamine Dimesylate , 2012, CNS Drugs.

[20]  A. Childress.  Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder , 2012, Advances in Therapy.

[21]  M. Corcoran,et al.  Pharmacokinetics of Lisdexamfetamine Dimesylate after Targeted Gastrointestinal Release or Oral Administration in Healthy Adults , 2012, Drug Metabolism and Disposition.

[22]  F. Sallee,et al.  The use of lisdexamfetamine dimesylate for the treatment of ADHD , 2012, Expert review of neurotherapeutics.

[23]  Michael L. Pucci,et al.  Pharmacokinetic Variability of Long-Acting Stimulants in the Treatment of Children and Adults with Attention-Deficit Hyperactivity Disorder , 2010, CNS drugs.

[24]  Patrick Martin,et al.  Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers , 2010, Journal of clinical pharmacology.

[25]  O. Bukstein,et al.  Management of the adolescent with substance use disorders and comorbid psychopathology. , 2010, Child and adolescent psychiatric clinics of North America.

[26]  M. Pennick.  Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine , 2010, Neuropsychiatric disease and treatment.

[27]  G. Mattingly.  Lisdexamfetamine Dimesylate: A Prodrug Stimulant for the Treatment of ADHD in Children and Adults , 2010, CNS Spectrums.

[28]  David W Goodman,et al.  Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. , 2010, P & T : a peer-reviewed journal for formulary management.

[29]  J. Stark,et al.  Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. , 2010, Clinical therapeutics.

[30]  S. Cheetham,et al.  The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety , 2009, Neuropharmacology.

[31]  P. Bhattacharya,et al.  Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[32]  K. Lasseter,et al.  Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults , 2009, Postgraduate medicine.

[33]  D. Jasinski,et al.  Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers , 2009, Journal of psychopharmacology.

[34]  A. Arnsten,et al.  The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex. , 2009, The Journal of pediatrics.

[35]  Brian J. Cowles.  Lisdexamfetamine for Treatment of Attention-Deficit/Hyperactivity Disorder , 2009, The Annals of pharmacotherapy.

[36]  S. Krishnan,et al.  Relative Bioavailability of Lisdexamfetamine 70‐mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single‐Dose, Crossover Pharmacokinetic Study , 2008, Journal of clinical pharmacology.

[37]  R. Doyle,et al.  Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder , 2008, Postgraduate medicine.

[38]  J. Stark,et al.  Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers , 2008, Current medical research and opinion.

[39]  J. Biederman,et al.  Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study , 2007, Biological Psychiatry.

[40]  S. Krishnan,et al.  An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes , 2007, Drug Metabolism and Disposition.

[41]  N. Volkow,et al.  Abuse of prescription drugs and the risk of addiction. , 2006, Drug and alcohol dependence.

[42]  Patrick Martin,et al.  Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate , 2011, Clinical drug investigation.

[43]  J. Najib.  The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. , 2009, Clinical therapeutics.

[44]  J. Stark,et al.  Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate , 2008, Clinical drug investigation.